These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844 [TBL] [Abstract][Full Text] [Related]
4. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. Stairs DB; Nakagawa H; Klein-Szanto A; Mitchell SD; Silberg DG; Tobias JW; Lynch JP; Rustgi AK PLoS One; 2008; 3(10):e3534. PubMed ID: 18953412 [TBL] [Abstract][Full Text] [Related]
9. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Phillips RW; Frierson HF; Moskaluk CA Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477 [TBL] [Abstract][Full Text] [Related]
10. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Souza RF; Krishnan K; Spechler SJ Am J Physiol Gastrointest Liver Physiol; 2008 Aug; 295(2):G211-8. PubMed ID: 18556417 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus. Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310 [TBL] [Abstract][Full Text] [Related]
13. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Huo X; Zhang HY; Zhang XI; Lynch JP; Strauch ED; Wang JY; Melton SD; Genta RM; Wang DH; Spechler SJ; Souza RF Gastroenterology; 2010 Jul; 139(1):194-203.e1. PubMed ID: 20303354 [TBL] [Abstract][Full Text] [Related]
14. Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus. Gotovac JR; Kader T; Milne JV; Fujihara KM; Lara-Gonzalez LE; Gorringe KL; Kalimuthu SN; Jayawardana MW; Duong CP; Phillips WA; Clemons NJ Cell Mol Gastroenterol Hepatol; 2021; 12(2):689-713. PubMed ID: 33774196 [TBL] [Abstract][Full Text] [Related]
15. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218 [TBL] [Abstract][Full Text] [Related]
16. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828 [TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis of Barrett's esophagus--new findings in the experimental studies of duodenal reflux models]. Hattori T; Mukaisho K; Miwa K Nihon Rinsho; 2005 Aug; 63(8):1341-9. PubMed ID: 16101219 [TBL] [Abstract][Full Text] [Related]
18. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. Smith CM; Watson DI; Leong MP; Mayne GC; Michael MZ; Wijnhoven BP; Hussey DJ World J Gastroenterol; 2011 Feb; 17(8):1036-44. PubMed ID: 21448356 [TBL] [Abstract][Full Text] [Related]